Lv63
1890 积分 2022-01-04 加入
High-throughput screening for class I peptide MHC binding via yeast surface display
1个月前
已完结
Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies
3个月前
已完结
Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies
3个月前
已完结
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
3个月前
已完结
A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL
4个月前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
4个月前
已完结
Implications of IL-21 in solid tumor therapy
4个月前
已完结
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
4个月前
已完结
Engineering T-cell receptor–like antibodies for biologics and cell therapy
4个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
4个月前
已完结
皖公网安备34019202002308
